Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2 β
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β Laboratory Investigation 98, 117 (January 2018). doi:10.1038/labinvest.2017.106 Authors: Mieke Raap, Malte Gronewold, Henriette Christgen, Silke Glage, Mohammad Bentires-Alj, Shany Koren, Patrick W Derksen, Mirjam Boelens, Jos Jonkers, Ulrich Lehmann, Friedrich Feuerhake, Elna Kuehnle, Oleg Gluz, Ronald Kates, Ulrike Nitz, Nadia Harbeck, Hans H Kreipe &Matthias Christgen
ConclusionsWe observed that an increasing proportion of women are using ET for LCIS management, but geographical differences exist. Health insurance status played an important role in the underutilization of ET. Further research is needed to assess patient outcomes given the variations in management of LCIS.
AbstractPurposeIncrease in in situ breast cancer (BCIS) incidence has been reported across Europe and the USA. However, little is known about the trends in BCIS incidence in regions without population-based mammographic screening programs. We set out to investigate these trends in Zurich, Switzerland, where only opportunistic mammographic screening exists.MethodsData from 989 women diagnosed with a primary BCIS between 2003 and 2014 were used in our analyses. Age-standardized incidence rates per 100,000 person-years (ASR) were computed per year. Additional analyses by BCIS subtype, by age group at diagnosis and by incidenc...
ConclusionsHigh-risk women with greater than minimal BPE at screening MRI have increased risk of future breast cancer.
Authors: Thomas PS Abstract Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammographic or palpable finding. Although AH and LCIS are benign breast disease, further management is necessary due to their high-risk nature and premalignant potential. Over the decades, management of AH and LCIS has changed as more is learned about these disease processes. This review explores the studies evaluating the risk for breast cancer in women with A...
CONCLUSIONS: Our findings support the contention that LCIS has a repertoire of somatic genetic alterations similar to that of ILCs, and likely constitutes a non-obligate precursor of breast cancer. Intra-lesion genetic heterogeneity is observed in LCIS and should be considered in studies aiming to develop biomarkers of progression from LCIS to more advanced lesions. PMID: 30185420 [PubMed - as supplied by publisher]
CONCLUSION: We conclude that the upgrade rate for high-risk lesions at MRI-VAB at surgical excision is low. Surgical excision is warranted for ADH and combined ALH-LCIS lesions. For other lesions, a multidisciplinary approach to decide on personalized management may be appropriate. Advancesin knowledge: Surgical excision is warranted for ADH lesions and combined ALH-LCIS lesions identified at breast MRI-VAB. A multidisciplinary approach to patient management of other high-risk lesions may be appropriate. PMID: 29947265 [PubMed - as supplied by publisher]
Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ, Published online: 21 June 2018; doi:10.1038/s41416-018-0120-zValidation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.
In the eighth edition of the American Joint Committee on Cancer staging system for breast cancer, the definitions for T (tumor), N (nodes), and M (metastases) remain substantially unchanged but with clarifications for certain categories that may have been problematic for pathologists and clinicians. The principal change is the decision to exclude lobular carcinoma in situ from T classification. In contrast, there is a major change in how stage is determined by introducing a new clinical prognostic stage and a new pathological prognostic stage. These prognostic stages incorporate information about grade, estrogen receptor e...
Conclusions High-risk women with greater than minimal BPE at screening MRI have increased risk of future breast cancer.